In this respect, the multifaceted properties of CD6 and its ligands can be used to leverage its tumour specificity, infiltration capacity, immunomodulatory potential, and the on-target off-tumour toxicity observed in novel immunotherapeutic approaches, turning CD6 into an exciting candidate for alternative and adjunctive cancer immunotherapies. The gene discussed is CD6; the disease is neoplasm.